Researchers at King’s College London have developed a new antibody therapy that can slow down the growth of treatment-resistant and triple negative breast cancer, two forms of the disease that are particularly hard to treat. In a study published today in Cancer Research , the scientists report that their novel approach to engineering antibodies significantly improved the engagement of immune cells against cancer cells in animal models, increasing the survival rate.

“We have designed our antibodies to make them interact better and harness the immune system in a way that has never been done or tested in cancer before,” said senior author Sophia Karagiannis, PhD, professor of translational cancer immunology and immunotherapy at King’s College London. “If it proves successful, it coul

See Full Page